Source: REUTERS

Spinifex: Novartis agrees to buy biotech firm Spinifex Pharmaceuticals

ZURICH (Reuters) - Swiss drugmaker Novartis AG will buy U.S.-Australian biotech company Spinifex Pharmaceuticals, a chronic pain specialist, the companies said in separate statements on Monday.

Read full article »
Spinifex's Competitors | Spinifex's News | Spinifex's Financials
Stay up-to-date with the latest news on Spinifex Pharmaceuticals Pty. Ltd.
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Tom McCarthy's photo - President & CEO of Spinifex Pharmaceuticals Pty. Ltd.

President & CEO

Tom McCarthy

CEO Approval Rating

66/100

Read more
Stay up-to-date with the latest news on Spinifex Pharmaceuticals Pty. Ltd.